[Functional and motor gastrointestinal disorders].
Functional gastrointestinal (GI) and motility disorders generate a large volume of consultations in gastroenterology and primary care offices. The present article summarizes the most interesting studies presented in the annual meeting of the American Gastroenterological Association 2008. For all functional GI disorders, studies were presented that evaluated the applicability of diagnostic criteria in clinical practice and new data were presented on physiopathology (for example, mediation by neuromodulators such as serotonin, microinflammation, alterations in intestinal microbiota, and psychological factors). More specifically, the therapeutic results of new prokinetic agents in functional dyspepsia, such as acotiamide, were presented. This agent has been demonstrated to have good efficacy in symptom control, especially in patients with postprandial distress syndrome. In irritable bowel syndrome, data were presented on several drugs that act through diverse mechanisms of action and have been shown to be more effective than placebo in symptom control. These drugs include antiinflammatory agents such as mesalazine, antibiotics such as rifaximin, probiotics with distinct bacterial strains, and prokinetic agents such as lubiprostone. Highly promising results have been obtained in the treatment of constipation with prokinetics such as prucalopride and with novel laxatives such as linaclotide, as well as with techniques that continue to be shown to be effective such as anorectal biofeedback, which is also highly useful in patients with fecal incontinence. Another disorder that is less frequent but highly difficult to treat is gastroparesis. For several years, treatment in the most severe cases has consisted of implantation of a gastric pacemaker. Although the results are far from perfect, new data were presented that allow better patient selection to achieve greater symptom control. The list of new advances, both in knowledge of the physiopathology of these disorders and on their treatments, is extensive. Consequently, 2008 has been a good year in terms of the useful information gathered for physicians interested in functional GI and motor disorders.
Mearin
Fermín
F
Servicio de Aparato Digestive, Instituto de Trastornos Funcionales y Motores Digestivos, Centro Medico Teknon, Barcelona, España. mearin@dr.teknon.es
Perelló
Antonia
A
Balboa
Agustín
A
D003248:Constipation / Q000188:drug therapy / Q000209:etiology; D003680:Deglutition Disorders / Q000175:diagnosis / Q000188:drug therapy; D004802:Eosinophilia / Q000175:diagnosis / Q000628:therapy; D004941:Esophagitis / Q000175:diagnosis / Q000628:therapy; D005767:Gastrointestinal Diseases / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy / Q000209:etiology